Genedx, INC.

Clinical genetic testing company

Based in MD

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $88K in lobbying spend across 6 quarterly filings, Genedx, INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2021 to 2022.

$88K
Total Spend
2
Years Active
1
Firms Hired
3
Lobbyists Deployed
2
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2021$0
2022$88K

Issues Lobbied

Medicare/MedicaidMED

Lobbying Firms

Ipolicy Solutions

Lobbyists

Jennifer LeibMegan Anderson BrooksJay Qiu

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, MED

  • •Oversight of diagnostics
  • •Medicaid coverage of genetic tests
  • •HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage
  • •HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

American Society of Addiction Medicine
$1.9M total spend
Association for Molecular Pathology
$1.5M total spend
Cystic Fibrosis Foundation
$1.1M total spend
Immune Deficiency Foundation
$560K total spend
US Against Alzheimer's
$420K total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.